Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

A Crossover Study in the Treatment of Patients With COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00462540
Recruitment Status : Completed
First Posted : April 19, 2007
Last Update Posted : March 4, 2009
Information provided by:

Brief Summary:
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Formoterol Fumurate inhalation solution 20 mcg Drug: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2007
Actual Primary Completion Date : September 2007
Actual Study Completion Date : October 2007

Primary Outcome Measures :
  1. Lung function after 2 weeks of treatment

Secondary Outcome Measures :
  1. Lung function at each time point, patient questionnaires, medication compliance,
  2. adverse events, clinical labs, vital signs, ECGs, physical exams

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of COPD
  • Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day
  • Meet lung function requirements

Exclusion Criteria:

  • Diagnosis of Asthma
  • Significant disease other than COPD
  • Female pregnant or lactating or planning to become pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00462540

Layout table for location information
United States, California
Research Site
San Diego, California, United States, 92120
United States, Colorado
Research Site
Denver, Colorado, United States, 80206
Research Site
Wheat Ridge, Colorado, United States, 80033
United States, Florida
Research Site
Panama City, Florida, United States, 32405
Research Site
Pensacola, Florida, United States, 32504
United States, Idaho
Research Site
Coeur d'Alene, Idaho, United States, 83814
United States, Louisiana
Research Site
Sunset, Louisiana, United States, 70584
United States, North Carolina
Research Site
Charlotte, North Carolina, United States, 28207
United States, Oregon
Research Site
Portland, Oregon, United States, 97213
United States, South Carolina
Research Site
Gaffney, South Carolina, United States, 29340
Research Site
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Research Site
Johnson City, Tennessee, United States, 37601
United States, Texas
Research Site
San Antonio, Texas, United States, 78205
United States, Washington
Research Site
Spokane, Washington, United States, 99204
United States, West Virginia
Research Site
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators

Publications of Results:
Layout table for additonal information
Responsible Party: Director, Clinical Affairs, Dey Identifier: NCT00462540    
Other Study ID Numbers: 201-081
First Posted: April 19, 2007    Key Record Dates
Last Update Posted: March 4, 2009
Last Verified: March 2009
Keywords provided by Dey:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents
Cholinergic Antagonists
Cholinergic Agents